Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Asieris Pharmaceuticals logo — We strive for healthy and dignified lives!

Asieris Pharmaceuticals

We strive for healthy and dignified lives!

Founded 2010 United States United States 60 employees Series D Total: $1.19B Biotechnology, Health Care +1

General Information

Company Name Asieris Pharmaceuticals
Founded Year 2010
Location United States United States
Employees 60
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Asieris Pharmaceuticals. To contact Asieris Pharmaceuticals, visit asieris.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Asieris Pharmaceuticals compare?

A PDF of Asieris Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Asieris Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Asieris Pharmaceuticals

Asieris Pharmaceuticals is a biotechnology and pharmaceutical company striving to improve human health and dignity through innovative drug development. Founded in 2010, the company focuses on genitourinary tumors and other major diseases, with the aim of becoming a global pharma leader integrating R&D, manufacturing, and commercialization. In their latest funding round in November 2020, Asieris secured a CNY700.00M Series D investment, with participation from prominent investors including Qiming Venture Partners, In Capital, Gopher Asset Management, CICC, SAIC Capital, Homsun Capital, TriWise Capital, YF Capital, Haoshuo Zhier Fund, and Xiamen C&D Corporation. Asieris Pharmaceuticals has been dedicated to developing a proprietary R&D platform and core technologies to address unmet clinical needs. The company is committed to launching first-in-class drugs and innovative products while enhancing its pipeline for genitourinary diseases through strategic partnerships. Their forward-looking approach in product planning and life-cycle management aims to establish an outstanding portfolio covering diagnosis and treatment. Asieris is set to benefit more patients in China and globally with its best-in-class integrated diagnosis and treatment solutions. With a focus on cutting-edge technologies and therapeutics, Asieris Pharmaceuticals is well-positioned to make a significant impact in the biopharmaceutical industry.

Business keywords: pharmaceuticals, biotech, drug development, oncology, genitourinary tumors, global healthcare, R&D, innovation, clinical research, therapeutic areas, diagnosis and treatment solutions, strategic partnerships, multidrug-resistant infections, unmet clinical needs

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D CNY700.00M 10
Gopher Asset Management CICC SAIC Capital
Gopher Asset Management, CICC +8
11 Nov 2020
Series C CNY290.00M -
28 Jun 2020
Series C CNY100.00M -
24 Mar 2020
Series B CNY100.00M -
27 Dec 2017
Series A Undisclosed -
12 Dec 2016

Asieris Pharmaceuticals Alternatives & Competitors

View All Alternatives
Asieris Pharmaceuticals vs
AiViva Biopharma, Inc.
AiViva Biopharma, Inc. United States

Developing Novel, Localized Treatments in Oncology, Ophthalmology, Dermatology, and Urology to Trans...

16 employees
Biotechnology, Pharmaceutical
Compare Asieris Pharmaceuticals vs AiViva Biopharma, Inc.
Asieris Pharmaceuticals vs
Antengene
Antengene China

Treating Patients Beyond Borders.

Series C
69 employees
Biopharma, Biotechnology
Compare Asieris Pharmaceuticals vs Antengene
Asieris Pharmaceuticals vs
ArriVent Biopharma
ArriVent Biopharma

Accelerating the Global Development of Innovative Biopharmaceutical Products

IPO
79 employees
Biotechnology, Life Sciences
Also compare with: Asieris Pharmaceuticals vs Gan & Lee Pharmaceuticals Gan & Lee Pharmaceuticals View all alternatives

FAQ About Asieris Pharmaceuticals

We strive for healthy and dignified lives!
Asieris Pharmaceuticals was founded in 2010.
Asieris Pharmaceuticals is headquartered in United States.
Asieris Pharmaceuticals operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on pharmaceuticals, biotech, drug development and oncology.
Asieris Pharmaceuticals has approximately 60 employees.
Asieris Pharmaceuticals has completed 5 funding rounds, raising a total of $1.19B. The latest funding stage is Series D.
Top alternatives and competitors to Asieris Pharmaceuticals include AiViva Biopharma, Inc., Antengene, ArriVent Biopharma, Shorla Oncology, Biocidium Biopharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Asieris Pharmaceuticals and AiViva Biopharma, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Asieris Pharmaceuticals, https://bouncewatch.com/company/asieris-pharmaceuticals, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout